KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC)

被引：0

作者：

Frank, R. ^{[1
]}

Scheffler, M. ^{[1
]}

Michels, S. ^{[1
]}

Eisert, A. ^{[1
]}

Fischer, R. ^{[1
]}

Koenig, K. ^{[2
]}

Merkelbach-Bruse, S. ^{[3
]}

Serke, M. ^{[4
]}

Ko, Y. D. ^{[5
]}

Gerigk, U. ^{[6
]}

Geist, T. ^{[7
]}

Heukamp, L. ^{[3
]}

Buettner, R. ^{[3
]}

Wolf, J. ^{[1
]}

机构：

[1] Uniklin Koln, Dept Internal Med 1, LCGC, Cologne, Germany

[2] Uniklin Koln, Dept Pathol, Cologne, Germany

[3] Uniklin Koln, Inst Pathol, Cologne, Germany

[4] Lungenklin Hemer, Lungcanc, Hemer, Germany

[5] Johanniter Krankenhaus Bonn, Oncol, Bonn, Germany

[6] Evangel Kliniken Johanniter & Waldkrankenhaus Bon, Thoraxchirurg, Bonn, Germany

[7] Kaiserswerther Diakonie, Klin Pneumol Allergol Schlaf & Beatmungsmed, Pneumol, Dusseldorf, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31766-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3125

引用

页码：S645 / S645

页数：1

共 50 条

[31] KEAP1/NRF2 (NFE2L2) mutations in NSCLC-Fuel for a superresistant phenotype?
Dempke, Wolfram C. M.
Reck, Martin
LUNG CANCER, 2021, 159 : 10 - 17
[32] Association of germline mutations in EGFR and ABCG2 with gefitinib response in patients with non-small cell lung cancer (NSCLC).
Gregorc, V
Cusatis, G
Spreafico, A
Amoroso, MG
Gianmarco, A
Ingersoll, RG
Sparreboom, A
Villa, E
Hidalgo, M
Baker, SD
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 197S - 197S
[33] DDR2 mutations in non-small cell lung cancer (NSCLC): clinical, histological and genetic characteristics
Scheffler, M.
Michels, S.
Gardizi, M.
Koenig, K.
Merkelbach-Bruse, S.
Stamm, K.
Heukamp, L. C.
Buettner, R.
Wolf, J.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 66 - 66
[34] Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer
Feng, Shuidong
Ling, Hongyan
Guo, Hui
Tong, Lingling
Hu, Guobin
Liao, Li
Lv, Xueying
Tan, Hongzhuan
Wu, Yimou
JOURNAL OF THORACIC DISEASE, 2014, 6 (05) : 503 - 506
[35] Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas
Jin, Xing
Zheng, Yuansheng
Chen, Zhencong
Wang, Fei
Bi, Guoshu
Li, Ming
Liang, Jiaqi
Sui, Qihai
Bian, Yunyi
Hu, Zhengyang
Qiao, Yulei
Xu, Songtao
CANCER MEDICINE, 2021, 10 (23): : 8673 - 8692
[36] Imaging mutations in non small cell lung cancer (NSCLC)
Haslop, Anna
Robins, Edward George
Goggi, Julian Luke
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S337 - S337
[37] PD-L1 expression, EGFR mutations (EGFRm) and KRAS mutations (KRASm) in stage III unresectable non-small cell lung cancer (NSCLC) patients
Cronin-Fenton, Deirdre
Dalvi, Tapashi
Hedgeman, Elizabeth
Norgaard, Mette
Pedersen, Lars
Hansen, Hanh
Fryzek, Jon
Walker, Jill
Mellemgaard, Anders
Rasmussen, Torben R.
Shire, Norah
Rigas, James
Potter, Danielle
Hamilton-Dutoit, Stephen
Sorensen, Henrik T.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 384 - 385
[38] KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC
Arolt, Christoph
Dugan, Margaret
Wild, Robert
Richartz, Vanessa
Holz, Barbara
Scheel, Andreas H.
Braegelmann, Johannes
Wagener-Ryczek, Svenja
Merkelbach-Bruse, Sabine
Wolf, Juergen
Buettner, Reinhard
Catanzariti, Luigi
Fler, Matthias Schef
Hillmer, Axel M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : 1550 - 1567
[39] Prognostic significance and origin of plasma KRAS mutations in patients with non-small cell lung cancer (NSCLC)
Gautschi, Oliver
Ziegler, Annemarie
Huegli, Barbara
Gugger, Mathias
Ratschiller, Daniel
Mack, Philip C.
Kung, Hsing-Jien
Stahel, Rolf A.
Gandara, David R.
Betticher, Daniel C.
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S443 - S443
[40] Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients
Wang, S.
Xu, C.
Wang, W.
Zhuang, W.
Song, Z.
Zhu, Y.
Chen, R.
Guan, Y.
Yi, X.
Chen, Y.
Chen, G.
Fang, M.
Lv, T.
Song, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1941 - S1941

← 1 2 3 4 5 →